ATE361067T1 - Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungen - Google Patents
Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungenInfo
- Publication number
- ATE361067T1 ATE361067T1 AT02745640T AT02745640T ATE361067T1 AT E361067 T1 ATE361067 T1 AT E361067T1 AT 02745640 T AT02745640 T AT 02745640T AT 02745640 T AT02745640 T AT 02745640T AT E361067 T1 ATE361067 T1 AT E361067T1
- Authority
- AT
- Austria
- Prior art keywords
- alzheimer
- treatment
- neurodegenerative diseases
- inhibitors
- tau aggregation
- Prior art date
Links
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 3
- 238000004220 aggregation Methods 0.000 title abstract 2
- 230000002776 aggregation Effects 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 abstract 2
- 230000004770 neurodegeneration Effects 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 241000276398 Opsanus tau Species 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 235000012711 vitamin K3 Nutrition 0.000 abstract 1
- 239000011652 vitamin K3 Substances 0.000 abstract 1
- 229940041603 vitamin k 3 Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0117326.9A GB0117326D0 (en) | 2001-07-16 | 2001-07-16 | Napthoquinone-type inhibitors of protein aggregation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE361067T1 true ATE361067T1 (de) | 2007-05-15 |
Family
ID=9918593
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02745640T ATE361067T1 (de) | 2001-07-16 | 2002-07-16 | Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungen |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7605179B2 (de) |
| EP (1) | EP1408952B1 (de) |
| JP (1) | JP5147157B2 (de) |
| CN (1) | CN1313088C (de) |
| AT (1) | ATE361067T1 (de) |
| AU (1) | AU2002317354B2 (de) |
| CA (1) | CA2451422C (de) |
| DE (1) | DE60219917T2 (de) |
| ES (1) | ES2287292T3 (de) |
| GB (1) | GB0117326D0 (de) |
| SG (1) | SG148846A1 (de) |
| WO (1) | WO2003007933A1 (de) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9506197D0 (en) | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
| GB0100119D0 (en) | 2001-01-03 | 2001-02-14 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| GB0101049D0 (en) | 2001-01-15 | 2001-02-28 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| GB0106953D0 (en) | 2001-03-20 | 2001-05-09 | Univ Aberdeen | Neufofibrillary labels |
| WO2005000288A2 (en) * | 2003-06-23 | 2005-01-06 | Neurochem (International) Limited | Treatment of protein aggregation disorders |
| WO2005053609A2 (en) * | 2003-11-26 | 2005-06-16 | Guilford Pharmaceuticals Inc. | Methods of nad+-dependent deacetylase inhibitors |
| WO2006007864A1 (en) * | 2004-07-17 | 2006-01-26 | Max Planck Geselllschaft Zur Förderung Der Wissenschaft | Treating neurodegenerative conditions |
| FR2874923B1 (fr) * | 2004-09-07 | 2006-10-27 | Trophos Sa | Application a titre de medicaments de derives du 3, 5-seco-4-nor-cholestane, compositions pharmaceutiques les renfermant, nouveaux derives et leur procede de preparation |
| JP5186212B2 (ja) | 2004-09-23 | 2013-04-17 | ウィスタ ラボラトリーズ リミテッド | メチルチオニニウム塩化物（ｍｔｃ）などのジアミノフェノチアジニウム化合物を化学合成および精製する方法 |
| JP4734602B2 (ja) | 2004-12-21 | 2011-07-27 | Ｄｏｗａエレクトロニクス株式会社 | 保存安定性に優れた窒化鉄系磁性粉末 |
| JP4822312B2 (ja) * | 2005-05-13 | 2011-11-24 | 学校法人慶應義塾 | ナフトキノン誘導体化合物 |
| KR100699945B1 (ko) * | 2005-11-24 | 2007-03-26 | (주) 디지탈바이오텍 | 나프토퀴논계 화합물을 함유하는 인지기능 장애의 예방 및 치료용 조성물 |
| CN104606199B (zh) | 2006-03-29 | 2022-09-13 | 维斯塔实验室有限公司 | 3,7-二氨基-10h-吩噻嗪化合物盐及其用途 |
| DK2004155T3 (en) | 2006-03-29 | 2018-04-30 | Wista Lab Ltd | PROTEIN AGGREGATION INHIBITORS |
| JP5432710B2 (ja) * | 2006-06-23 | 2014-03-05 | ザ・フェインスタイン・インスティチュート・フォー・メディカル・リサーチ | Ａβ及びシヌクレイン凝集の阻害剤 |
| RU2446793C2 (ru) * | 2007-04-05 | 2012-04-10 | Й-Оил Миллс, Инц. | Транквилизатор и функциональный продукт питания |
| WO2009033151A1 (en) * | 2007-09-07 | 2009-03-12 | The Trustees Of Columbia University In The City Of New York | Tau protein screening assay |
| EP2060256A1 (de) * | 2007-11-16 | 2009-05-20 | Gnosis S.p.A. | Auf Menaquinolen basierende pharmazeutische und nutrazeutische Zusammensetzungen |
| GB0816269D0 (en) | 2008-09-05 | 2008-10-15 | Univ Ramot | Naphthoquinone derivatives useful for prevention of amyloid deposits and treatment of alzheimers disease |
| JP2013529181A (ja) | 2010-03-25 | 2013-07-18 | ザ ジェイ． デヴィッド グラッドストーン インスティテューツ | 神経障害を治療するための組成物および方法 |
| US9320793B2 (en) * | 2010-07-14 | 2016-04-26 | Acumen Pharmaceuticals, Inc. | Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42 |
| SG187744A1 (en) * | 2010-08-06 | 2013-03-28 | Edison Pharmaceuticals Inc | Treatment of mitochondrial diseases with naphthoquinones |
| US8703137B2 (en) | 2011-01-31 | 2014-04-22 | Intellect Neurosciences Inc. | Treatment of tauopathies |
| CA2827027C (en) | 2011-02-11 | 2019-06-04 | Wista Laboratories Ltd. | Phenothiazine diaminium salts and their use |
| EP2699157B1 (de) | 2011-04-21 | 2018-03-14 | The Regents of The University of California | Funktionalisierte magnetische nanoteilchen und ihre verwendung bei der abbildung von amyloider plaque und neurofibrillären bündeln |
| WO2012170773A1 (en) * | 2011-06-08 | 2012-12-13 | Edison Pharmaceuticals, Inc. | Adjunctive therapy for the treatment of mitochondrial disorders with quinones and naphthoquinones |
| JP6126531B2 (ja) | 2011-10-03 | 2017-05-10 | 国立研究開発法人国立長寿医療研究センター | タウ凝集阻害剤 |
| GB2520111A (en) | 2012-02-05 | 2015-05-13 | Biodesy Inc | Methods for identifying modulators of Ras using nonlinear techniques |
| DK2885010T3 (da) | 2012-08-16 | 2020-02-03 | Ipierian Inc | Fremgangsmåder til behandling med tauopati |
| CA2883879A1 (en) | 2012-09-07 | 2014-03-13 | Edison Pharmaceuticals, Inc. | Quinone derivatives for use in the modulation of redox status of individuals |
| WO2014066744A2 (en) | 2012-10-25 | 2014-05-01 | True North Therapeutics, Inc. | Anti-complement c1s antibodies and uses thereof |
| PL2914291T3 (pl) | 2012-11-02 | 2022-10-03 | Bioverativ Usa Inc. | Przeciwciała anty-C1s dopełniacza i ich zastosowania |
| US9907799B2 (en) | 2013-04-02 | 2018-03-06 | The Doshisha | Tau aggregation inhibitor |
| LT3007726T (lt) | 2013-06-10 | 2020-09-10 | Ipierian, Inc. | Tautopatijos gydymo būdai |
| JP6518656B2 (ja) * | 2013-06-13 | 2019-05-22 | バイオデシー， インコーポレイテッド | 標的生体実体を標的にする生化学実体候補をスクリーニングする方法 |
| US20150166476A1 (en) * | 2013-12-17 | 2015-06-18 | Yi-Cheng Chen | Methods for treating neurodegenerative diseases associated with aggregation of amyloid-beta |
| EP3237906B8 (de) | 2014-12-23 | 2020-10-28 | Bluelight Therapeutics, Inc. | Befestigung von proteinen an schnittstellen zur verwendung in nicht-linearer optischer detektion |
| AU2018389092B2 (en) | 2017-12-19 | 2023-08-24 | Synergia Life Sciences Pvt. Ltd. | Vitamin K2 compositions for the treatment of drug induced neuropathy |
| US11911349B2 (en) | 2018-03-30 | 2024-02-27 | Nattopharma As | Rapidly improving vascular conditions by administering vitamin K |
| CA3135170A1 (en) | 2019-04-05 | 2020-10-08 | Tauc3 Biologics Limited | Anti-tauc3 antibodies and uses thereof |
| CN110025624B (zh) * | 2019-05-29 | 2021-04-02 | 济宁医学院附属医院 | 萘醌苷类化合物在老年痴呆中的应用及其药物制备 |
| CN112778092B (zh) * | 2020-12-31 | 2023-03-24 | 玉溪健坤生物药业有限公司 | 一种还原型维生素k2的制备方法及其用途 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59175449A (ja) * | 1983-03-26 | 1984-10-04 | Kyushu Kogyo Daigaku | シコニンの製造法 |
| JPS61143334A (ja) * | 1984-12-18 | 1986-07-01 | Mitsui Petrochem Ind Ltd | ５，８−ジヒドロキシ−１，４−ナフトキノン誘導体 |
| US4897388A (en) * | 1988-12-20 | 1990-01-30 | Geriatric Research Institute, Inc. | Method of treating Alzheimer's disease |
| ES2149168T3 (es) | 1991-02-04 | 2000-11-01 | Ks Biomedix Ltd | Derivados de naftoquinona para el tratamiento de la inflamacion cronica. |
| WO1993011231A1 (en) | 1991-12-06 | 1993-06-10 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Tools for the diagnosis and treatment of alzheimer's disease |
| EP0778773A1 (de) | 1994-08-08 | 1997-06-18 | Albert Einstein College Of Medicine Of Yeshiva University | Verfahren zur behandlung und/oder vorbeugung von alzheimer'sche krankheit mit phenothiazine und/oder thioxanthene |
| JPH08193026A (ja) * | 1995-01-12 | 1996-07-30 | Teijin Ltd | アミロイドβ蛋白凝集・沈着阻害剤 |
| DE19504003A1 (de) * | 1995-02-08 | 1996-08-14 | Martin Dr Kohlmeier | Verwendungen eines Vitamins der K-Gruppe |
| GB9506197D0 (en) | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
| US5804601A (en) | 1995-04-10 | 1998-09-08 | Takeda Chemical Industries, Ltd. | Aromatic hydroxamic acid compounds, their production and use |
| KR0180791B1 (ko) * | 1995-07-24 | 1999-05-15 | 김용옥 | 6-치환-5,8-디옥시-1,4-나프토퀴논 유도체, 그의 제조방법 및 그의 항암제로서의 용도 |
| JP3809014B2 (ja) * | 1998-05-22 | 2006-08-16 | 花王株式会社 | 養毛・育毛剤 |
| US20020040011A1 (en) | 2000-06-01 | 2002-04-04 | Brown Dennis M. | Naphthoquinone compositions and uses thereof |
| US20020016372A1 (en) | 2000-07-31 | 2002-02-07 | Allison Anthony Clifford | Method for preventing and treating alzheimer's disease and brain damage associated with cardiov ascular disease and head injury |
| GB0100119D0 (en) | 2001-01-03 | 2001-02-14 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| GB0101049D0 (en) | 2001-01-15 | 2001-02-28 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| GB0106953D0 (en) | 2001-03-20 | 2001-05-09 | Univ Aberdeen | Neufofibrillary labels |
| US6953974B2 (en) | 2003-08-26 | 2005-10-11 | Texas Instruments Incorporated | EEPROM device and method for providing lower programming voltage |
| GB0322756D0 (en) | 2003-09-29 | 2003-10-29 | Univ Aberdeen | Methods of chemical synthesis |
| ES2409683T3 (es) | 2004-09-23 | 2013-06-27 | Wista Laboratories Ltd. | Procedimientos de síntesis química y purificación de compuestos de diaminofenotiazinio que incluyen cloruro de metiltioninio (CMT) |
-
2001
- 2001-07-16 GB GBGB0117326.9A patent/GB0117326D0/en not_active Ceased
-
2002
- 2002-07-16 AU AU2002317354A patent/AU2002317354B2/en not_active Expired
- 2002-07-16 JP JP2003513541A patent/JP5147157B2/ja not_active Expired - Lifetime
- 2002-07-16 WO PCT/GB2002/003269 patent/WO2003007933A1/en not_active Ceased
- 2002-07-16 US US10/483,266 patent/US7605179B2/en not_active Expired - Lifetime
- 2002-07-16 DE DE60219917T patent/DE60219917T2/de not_active Expired - Lifetime
- 2002-07-16 CA CA2451422A patent/CA2451422C/en not_active Expired - Lifetime
- 2002-07-16 EP EP02745640A patent/EP1408952B1/de not_active Expired - Lifetime
- 2002-07-16 AT AT02745640T patent/ATE361067T1/de active
- 2002-07-16 CN CNB028177207A patent/CN1313088C/zh not_active Expired - Lifetime
- 2002-07-16 SG SG200600959-1A patent/SG148846A1/en unknown
- 2002-07-16 ES ES02745640T patent/ES2287292T3/es not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP1408952B1 (de) | 2007-05-02 |
| JP5147157B2 (ja) | 2013-02-20 |
| US7605179B2 (en) | 2009-10-20 |
| US20050107472A1 (en) | 2005-05-19 |
| JP2004534854A (ja) | 2004-11-18 |
| GB0117326D0 (en) | 2001-09-05 |
| CN1313088C (zh) | 2007-05-02 |
| SG148846A1 (en) | 2009-01-29 |
| WO2003007933A1 (en) | 2003-01-30 |
| DE60219917T2 (de) | 2008-01-17 |
| EP1408952A1 (de) | 2004-04-21 |
| ES2287292T3 (es) | 2007-12-16 |
| CA2451422C (en) | 2010-10-19 |
| AU2002317354B2 (en) | 2007-07-19 |
| HK1063012A1 (en) | 2004-12-10 |
| CA2451422A1 (en) | 2003-01-30 |
| CN1553800A (zh) | 2004-12-08 |
| DE60219917D1 (de) | 2007-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60219917D1 (de) | Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungen | |
| ATE409176T1 (de) | 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen | |
| EA200900802A1 (ru) | Способы и композиции для лечения амилоидных заболеваний | |
| EA200600078A1 (ru) | Способы и композиции для лечения амилоидных заболеваний | |
| DK1465626T3 (da) | Farmaceutiske præparater (kit) der omfatter dihydropyridinonforbindelser og et immunregulatorisk (eller et antiinflammatorisk) middel samt anvendelser deraf | |
| DE122012000007I1 (de) | Zusammenzetzungen und verfahren zur stabilisierungvon transthyretin und zur hemmung von transthyret infehlfaltung. | |
| ATE506951T1 (de) | Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit | |
| NO20071240L (no) | Terapeutiske anvendelser av RTP801 inhibitorer | |
| WO2005004803A3 (en) | Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease | |
| NO961326D0 (no) | Inhibitorer av | |
| ATE443043T1 (de) | Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer | |
| EA200501017A1 (ru) | Астма и модуляторы аллергических воспалений | |
| ATE517861T1 (de) | Benzylether und benzylaminoverbindungen als inhibitoren von beta-secretase zur behandlung von alzheimer-krankheit | |
| ATE480235T1 (de) | Verwendung von pramipexol zur behandlung von amyotrophischer lateralsklerose | |
| EA200600071A1 (ru) | Производные n-фенилпиперазина и способы профилактики или лечения заболеваний, связанных с 5ht-рецептором | |
| NO20063193L (no) | Fusjonerte pyrrolokarbazoler og fremgangsmater for fremstilling derav | |
| NO20044530L (no) | Fremgangsmate for behandling av kognitive forstyrrelser | |
| ATE432278T1 (de) | Verbindungen zur behandlung von krankheiten | |
| NO20015247L (no) | Glysinspaltingssysteminhibitorer som potensielle antipsykotika | |
| DE602004006118D1 (de) | 2,3,4,5-TETRAHYDROBENZOiFöi1,4öOXAZEPIN-5-CARBONSÄUREAMID DERIVATE ALS GAMMA-SECRETASE INHIBITOREN ZUR BEHANDLUNG VON ALZHEIMER | |
| ATE464048T1 (de) | Behandlung von alzheimer-krankheit und verwandten zuständen | |
| MXPA05013692A (es) | Metodos para tratar trastornos por acumulacion de proteina. | |
| ATE399758T1 (de) | Derivate von 1-phenylalkancarbonsäuren zur behandlung von neurodegenerativen krankheiten | |
| BR0314541A (pt) | Tratamento de demência e doença de parkinson | |
| DE602004024992D1 (de) | Verwendung von pyrazolopyridinen zur behandlung von kognitiven defiziten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1408952 Country of ref document: EP |